Entry Point Capital, LLC Taysha Gene Therapies, Inc. Transaction History
Entry Point Capital, LLC
- $188 Million
- Q2 2025
A detailed history of Entry Point Capital, LLC transactions in Taysha Gene Therapies, Inc. stock. As of the latest transaction made, Entry Point Capital, LLC holds 69,109 shares of TSHA stock, worth $201,107. This represents 0.08% of its overall portfolio holdings.
Number of Shares
69,109
Previous 135,897
49.15%
Holding current value
$201,107
Previous $188,000
15.43%
% of portfolio
0.08%
Previous 0.09%
Shares
6 transactions
Others Institutions Holding TSHA
# of Institutions
133Shares Held
165MCall Options Held
70KPut Options Held
4.7K-
Avoro Capital Advisors LLC New York, NY20MShares$58.2 Million0.45% of portfolio
-
Rtw Investments, LP New York, NY18.8MShares$54.7 Million0.43% of portfolio
-
Morgan Stanley New York, NY16.8MShares$49 Million0.0% of portfolio
-
Black Rock Inc. New York, NY11.7MShares$34.2 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.9MShares$31.7 Million0.0% of portfolio
About Taysha Gene Therapies, Inc.
- Ticker TSHA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,359,500
- Market Cap $141M
- Description
- Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for th...